Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
PPH is associated with almost 20 per cent of maternal mortality in India
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Self-collection devices designed for ease of use and safety
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Subscribe To Our Newsletter & Stay Updated
